These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 24689556)

  • 1. Cost effectiveness of a 92-gene assay for the diagnosis of metastatic cancer.
    Bentley TG; Schroeder BE; Schnabel CA; Erlander MG; Hsiao WC; Ortendahl JD; Broder MS
    J Med Econ; 2014 Aug; 17(8):527-37. PubMed ID: 24689556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.
    Elkin EB; Weinstein MC; Winer EP; Kuntz KM; Schnitt SJ; Weeks JC
    J Clin Oncol; 2004 Mar; 22(5):854-63. PubMed ID: 14990641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer.
    Vanderlaan BF; Broder MS; Chang EY; Oratz R; Bentley TG
    Am J Manag Care; 2011; 17(7):455-64. PubMed ID: 21819166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
    Snedecor SJ; Carter JA; Kaura S; Botteman MF
    Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Canadian cost-effectiveness analysis of transcatheter mitral valve repair with the MitraClip system in high surgical risk patients with significant mitral regurgitation.
    Cameron HL; Bernard LM; Garmo VS; Hernandez JB; Asgar AW
    J Med Econ; 2014 Aug; 17(8):599-615. PubMed ID: 24826880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
    Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
    Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
    Le QA; Hay JW
    Cancer; 2009 Feb; 115(3):489-98. PubMed ID: 19117341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.
    Casciano R; Chulikavit M; Di Lorenzo G; Liu Z; Baladi JF; Wang X; Robertson J; Garrison L
    Value Health; 2011; 14(6):846-51. PubMed ID: 21914504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
    Lu L; Peters J; Roome C; Stein K
    BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
    Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.
    Li Y; Bare LA; Bender RA; Sninsky JJ; Wilson LS; Devlin JJ; Waldman FM
    Mol Diagn Ther; 2015 Jun; 19(3):169-77. PubMed ID: 25926090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the cost-effectiveness of a routine versus an extensive laboratory work-up in the diagnosis of anaemia in Dutch general practice.
    Kip MM; Schop A; Stouten K; Dekker S; Dinant GJ; Koffijberg H; Bindels PJ; IJzerman MJ; Levin MD; Kusters R
    Ann Clin Biochem; 2018 Nov; 55(6):630-638. PubMed ID: 29199442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-Institutional, Prospective Clinical Utility Study Evaluating the Impact of the 92-Gene Assay (CancerTYPE ID) on Final Diagnosis and Treatment Planning in Patients With Metastatic Cancer With an Unknown or Unclear Diagnosis.
    Thomas SP; Jacobson LE; Victorio AR; Operaña TN; Schroeder BE; Schnabel CA; Braiteh F
    JCO Precis Oncol; 2018 Nov; 2():1-12. PubMed ID: 35135112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Pathology of Lung Cancer.
    J Saller J; Boyle TA
    Cold Spring Harb Perspect Med; 2022 Mar; 12(3):. PubMed ID: 34751163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.